News and Media

Latest News Release
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

Top feature box IMAGE ONLY - COMPANY NEWS

Press Releases

Cardinal Health Specialty Solutions Strengthens Cell and Gene Therapy Offering with PANTHERx Specialty Pharmacy Collaboration
04/26/2019

DUBLIN, Ohio, April 26, 2019 /PRNewswire/ -- To meet the growing needs of the market, Cardinal Health Specialty Solutions has strengthened its cell and gene therapy capability with a coordinated suite of specialty distribution, third-party logistics (3PL) services, and specialty pharmacy dispensing services. As part of this offering, Cardinal Health is announcing a collaboration with PANTHERx Specialty Pharmacy.

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. (PRNewsfoto/Cardinal Health)

PANTHERx Specialty Pharmacy, THE Rare Disease Specialty Pharmacy®, is the industry's leading, independent national specialty pharmacy. PANTHERx's mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions.

Cardinal Health has been delivering services for cell and gene therapies over the past few years using a "buy and bill" model, but identified an opportunity to augment its offering with specialty pharmacy services for manufacturers who require a different reimbursement approach.

"Our current work in cell and gene therapy has helped us recognize that manufacturers want to customize their channel plans for these high-touch products – and that may include using a specialty pharmacy. We are excited about our collaboration with PANTHERx because of their excellent reputation and deep experience with rare diseases. While we coordinate with many specialty pharmacies based on our clients' needs, we believe our relationship with PANTHERx gives us a unique advantage in the market," said Joe DePinto, President of Cardinal Health Specialty Solutions.  

"PANTHERx's collaboration with Cardinal Health Specialty Solutions in cell and gene therapy is unique and compelling. This relationship produces easier, more successful precision medicine launches, increased speed to therapy, and enhanced outcomes for patients," said Dr. Gordon J. Vanscoy, Chairman and Chief Executive Officer of PANTHERx Specialty Pharmacy. "This alliance with Cardinal Health generates real synergies as a result of our respective best-in-class businesses, a mutual desire to disrupt a fragmented distribution channel, and a shared can-do attitude. I am confident that our collaboration will generate tangible benefits for patients while dramatically simplifying the process for our biopharma partners."

Through its coordinated cell and gene offering, Cardinal Health provides manufacturers of precision medicines with a single source for distribution, 3PL services including order-to-cash management and reimbursement risk coverage through the 3PL title model, and specialty pharmacy dispensing. The company also supports cell and gene therapies with logistics and patient access services.

About Cardinal Health 
Cardinal Health, Inc. (NYSE: CAH) is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products, pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. To help combat prescription drug abuse, the company and its education partners created Generation Rx, a national drug education and awareness program. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 60 countries, Cardinal Health ranks #14 on the Fortune 500. For more information, visit cardinalhealth.com, follow @CardinalHealth on Twitter, Cardinal Health on Facebook and connect on LinkedIn at linkedin.com/ company/cardinal-health.

SOURCE Cardinal Health

For further information: Media: Brandi Martin, (614) 757-3383, Brandi.Martin@cardinalhealth.com; Investors: Lisa Capodici, (614) 757-5035, lisa.capodici@cardinalhealth.com
More Company News
08/01/2022

Greene previously served as SVP of EIT for the company's Pharmaceutical Segment DUBLIN, Ohio, Aug. 1, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that Michelle Greene has been...

07/22/2022

TO: ALL PERSONS AND ENTITIES THAT HELD CARDINAL HEALTH, INC. COMMON STOCK AS OF THE CLOSE OF TRADING ON MAY 25, 2022 AND THAT CONTINUE TO HOLD CARDINAL HEALTH COMMON STOCK AS OF THE CLOSE OF...

07/06/2022

Strengthening Cornerstone Rheumatology™ GPO as a leading rheumatology-focused GPO by providing innovative solutions and robust specialty drug access to over 1,300 rheumatology providers nationwide.

06/29/2022

Cardinal Health (NYSE: CAH) today announced the launch of an inventory reserve program that helps labs and health systems more accurately pre-order respiratory diagnostics before the onset of...

View all company news »

* Required Fields